Feasibility and Prospective Randomized Study of Transarterial Chemoembolization using Irinotecan Bead in Combination with Second Line Chemotherapy in the Treatment of Patients with Unresectable Metastatic Colorectal Cancer (PARAGON)

Trial Profile

Feasibility and Prospective Randomized Study of Transarterial Chemoembolization using Irinotecan Bead in Combination with Second Line Chemotherapy in the Treatment of Patients with Unresectable Metastatic Colorectal Cancer (PARAGON)

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 21 Sep 2015

At a glance

  • Drugs Irinotecan (Primary) ; Irinotecan
  • Indications Colorectal cancer; Liver metastases
  • Focus Therapeutic Use
  • Acronyms PARAGON-I
  • Most Recent Events

    • 26 Aug 2010 The trial has received FDA approval for continuing into a randomised phase IIb trial, with results expected in 2012, as reported in a Biocompatibles International media release.
    • 03 Jul 2010 Promising results have been presented at the World Congress for Gastro-Intestinal Cancer, as reported in a Biocampatibles International media release.
    • 16 Dec 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top